Acadia Pharmaceuticals Inc risk profile
22 Normal where most of the sector sits
Measured 1 September 2026 from ACAD's filed statements. Recomputed nightly.
22 (Normal), driven by Cash conversion at 42, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 30 | Normal | Stable | One-year price volatility — 38.3% |
| Operating pressure | 14 | Contained | Worsening | Costs outgrowing revenue — -1.2 percentage points |
| Cash conversion | 42 | Elevated | Worsening | Cash conversion — 0.28x |
| Leverage and coverage | 4 | Contained | Easing | Current ratio — 3.83x |
| Competitive position | 25 | Normal | Stable | Operating-margin gap against peers — +1.8 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Acadia Pharmaceuticals Inc